chr3-37047531-C-T
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM2PM5PP3_Moderate
The NM_000249.4(MLH1):c.1744C>T(p.Leu582Phe) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L582P) has been classified as Pathogenic.
Frequency
Consequence
NM_000249.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
not provided Pathogenic:2Uncertain:1
- -
This variant is denoted MLH1 c.1744C>T at the cDNA level, p.Leu582Phe (L582F) at the protein level, and results in the change of a Leucine to a Phenylalanine (CTC>TTC). This variant has been reported in individuals with early onset colorectal cancer, whose tumor testing demonstrated microsatellite instability and loss of MLH1, and also loss of PMS2 when performed, on mismatch repair immunohistochemistry (IHC) (Hendriks 2003, van Puijenbroek 2008, van der Klift 2016). Functional assays demonstrate MLH1 Leu582Phe to have reduced mismatch repair activity compared to wild-type, while other assays show defective MLH1-PMS2 dimerization (Drost 2010, Andersen 2012). MLH1 Leu582Phe was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Leucine and Phenylalanine share similar properties, this is considered a conservative amino acid substitution. MLH1 Leu582Phe occurs at a position that is conserved across species and is located in the PMS2/MLH3/PMS1 interaction domain and region of interaction with EXO1 (Pang 1997, Raevaara 2005, Hardt 2011, UniProt). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether MLH1 Leu582Phe is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. -
Not found in the total gnomAD dataset, and the data is high quality. Located in potentially critical domain of the protein. Assessment of experimental evidence suggests this variant results in abnormal protein function. -
Hereditary nonpolyposis colon cancer Pathogenic:1
Variant summary: MLH1 c.1744C>T (p.Leu582Phe) results in a non-conservative amino acid change located in the DNA mismatch repair protein Mlh1 C-terminus (IPR032189) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251262 control chromosomes. c.1744C>T has been reported in the literature in individuals affected with Hereditary Nonpolyposis Colorectal Cancer (e.g. Hendriks_2003, van der Klift_2016, van Puijenbroek_2008, Bouvet_2019; Labcorp, formerly Invitae). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (Drost_2009, Andersen_2012). The most pronounced variant effect results in significantly reduced MMR activity and abrogated interaction with PMS2. The following publications have been ascertained in the context of this evaluation (PMID: 22753075, 30998989, 20020535, 12547705, 17192056, 22949387, 18415027, 27435373). ClinVar contains an entry for this variant (Variation ID: 89870). Based on the evidence outlined above, the variant was classified as likely pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change replaces leucine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 582 of the MLH1 protein (p.Leu582Phe). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with Lynch syndrome (PMID: 12547705, 18415027, 27435373, 30998989; internal data). ClinVar contains an entry for this variant (Variation ID: 89870). Invitae Evidence Modeling incorporating data from in vitro experimental studies (internal data) indicates that this missense variant is not expected to disrupt MLH1 function with a negative predictive value of 95%. Experimental studies have shown that this missense change affects MLH1 function (PMID: 20020535, 22753075, 30998989). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.L582F pathogenic mutation (also known as c.1744C>T), located in coding exon 16 of the MLH1 gene, results from a C to T substitution at nucleotide position 1744. The leucine at codon 582 is replaced by phenylalanine, an amino acid with highly similar properties. This alteration showed moderate segregation with disease in a French family that met Amsterdam criteria where the colorectal tumor of the proband displayed loss of MLH1 protein expression on immunohistochemistry (personal communication with Universal Mutation Database depositor). This variant was identified as somatic in conjunction with a second somatic MLH1 pathogenic mutation in an MSI-H colorectal tumor with loss of MLH1 and PMS2 by IHC (Rigter LS et al. Gut, 2018 03;67:447-455). In a cell-free system designed to measure mismatch repair function, the MLH1 protein with the p.L582F variant was determined to have 26.5% relative repair activity compared to wild type (100%) (Drost M et al. Hum Mutat, 2010 Mar;31:247-53). In another in vitro assay, the binding capacity of the MLH1 p.L582F protein variant with PMS2 was measured in a GST pull-down assay and no binding was detected (Andersen SD et al. Hum. Mutat., 2012 Dec;33:1647-55). The p.L582F variant was also classified as potentially damaging in a methylation tolerance-based functional assay (Bouvet D et al. Gastroenterology, 2019 08;157:421-431). Based on internal structural analysis, L582F is more disruptive than an internally pathogenic variant in the same domain (Gueneau E et al. Nat Struct Mol Biol., 2013 Apr;20(4):461-8). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at